



*L-Uffiċċju tal-Uffiċjal Mediku Ewlieni*

*Office of the Chief Medical Officer*

**DH CIRCULAR No. 285/2011**  
DH 5579/2011

**23<sup>rd</sup> December 2011**

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy TechniciansNurses

**Re: Zoledronic acid 5mg vials**

It is being brought to your attention that steroid induced osteoporosis secondary to the Schedule V conditions listed in protocol 229 (attached) has been added as an indication for the prescription of Zoledronic acid 5mg vials.

All consultants can now prescribe zoledronic acid 5mg as per protocol 229 which is hereby attached.

Thank you

For your attention, please

Dr. Natasha Azzopardi Muscat  
Chief Medical Officer

## **Zoledronic acid 5mg vials**

**Prescriber's Criteria:** Consultant

**In-patient use:**

1. Paget's Disease
  
2. Patients with the following Schedule V conditions with steroid induced osteoporosis where steroids are prescribed:
  - Autoimmune Enteropathy
  - Collagen Disease
  - Crohn's and Ulcerative Colitis
  - Hepatic Cirrhosis
  - Malignancy
  - Multiple Sclerosis
  - Myasthenia Gravis
  - Renal disease
  - Respiratory disease

**Duration of Approval:**

1 year